Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 13.3.2017 | EN | Official Journal of the European Union | C 78/29 |

---

Judgment of the General Court of 26 January 2017 — Opko Ireland Global Holdings v EUIPO — Teva Pharmaceutical Industries (ALPHAREN)

(Case T-88/16)[(1)](#ntr1-C_2017078EN.01002902-E0001)

((EU trade mark - Opposition proceedings - Application for EU word mark ALPHAREN - Earlier national word marks ALPHA D3 - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 - Consideration of new evidence by the Board of Appeal following a judgment annulling a decision - Article 76(2) of Regulation No 207/2009))

(2017/C 078/40)

Language of the case: English

Parties

Applicant: Opko Ireland Global Holdings Ltd (Dublin, Ireland) (represented by: S. Malynicz QC, A. Smith and D. Meale, Solicitors)

Defendant: European Union Intellectual Property Office (represented by: A. Folliard-Monguiral, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO: Teva Pharmaceutical Industries Ltd (Jerusalem, Israel)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 16 December 2015 (Case R 2387/2014-5), relating to opposition proceedings between Teva Pharmaceutical Industries and Opko Ireland Global Holdings.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Opko Ireland Global Holdings Ltd to pay the costs. |

---

[Top](#document1)